Please contact us using the registration form below if you wish to express interest in potentially acquiring any of Astellas’ R&D programs listed below.
- An Astellas representative will contact you after your registration is received. (Please note that Astellas will determine the selected entity(-ies), if any, for further discussion according to the information submitted through this registration system.)
- An Astellas representative will provide selected entities with the Confidential Disclosure Agreement (CDA) template. Please fill in the necessary information on the CDA template and send it to the Astellas representative.
＜List of divestiture programs＞
Please click on each program name for a summary (non-confidential information).
|Program||Mechanism of Action|
|anti-NGF Monoclonal Antibody|
|nACh Alpha7 PAM|
|Dopamine D1 receptor positive allosteric modulator|
|Anti-human TIE2 Antibody|
|Antibody against thymic stromal lymphopoietin receptor|
Please fill out the form and agree with the submission terms.